The Daily Papule

Clin Derm

Ethical considerations of cosmetic glucagon-like peptide-1 receptor agonist prescribing in dermatology.

Jonnalagadda A, Lowry WP, Pathak GN, Choi E, Zhou AE, Grant-Kels JM

Clinics in DermatologyIn the feed 8 Sep 2026, published online 8 Sep 2026, issue 2026 Sep 08, added to PubMed 8 Sep 2026

Topics: Cosmetic, lasers, scars & woundsPractice, education & research

Abstract

Glucagon-like peptide-1 receptor agonists are increasingly used beyond approved metabolic indications, including for elective weight loss and aesthetic optimization. Dermatologists may receive requests to prescribe these agents and patients may experience downstream consequences such as facial volume loss and telogen effluvium. Although prescribing these medications for hidradenitis suppurativa or psoriasis can be medically justified and helpful, elective prescribing raises ethical concerns about nonmaleficence, scope of practice, prescribing cascades, patient autonomy, justice, and stewardship of limited resources. We discuss the ethical responsibilities of dermatologists considering prescribing glucagon-like peptide-1 receptor agonists for cosmetic purposes and propose practical guardrails to balance patient preferences with professional judgment and avoid iatrogenic harm.

Abstract from PubMed

PMID 42710721 · DOI 10.1016/j.clindermatol.2026.09.002